




RealRate

PHARMACEUTICAL 2020

Ocuphire Pharma Inc.
Rank 247 of 362



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Ocuphire Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ocuphire Pharma Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 134% points. The greatest weakness of Ocuphire Pharma Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 123% points.

The company's Economic Capital Ratio, given in the ranking table, is -302%, being 1.2% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	12,664
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,905
Liabilities, Non-Current	64
Other Assets	229
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	42
Other Net Income	2,580
Property and Equipment	76
Research and Development	5,477
Revenues	0
Selling, General and Administrative Expense	5,738

Output Variable	Value in 1000 USD
Assets	12,969
Liabilities	3,011
Expenses	11,215
Stockholders Equity	9,958
Net Income	-8,635
Comprehensive Net Income	-8,635
Economic Capital Ratio	-302%